Skip to main content
Clinical Trials/NCT03388437
NCT03388437
Completed
Not Applicable

Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation: A Randomised Control Trial

King Fahad Armed Forces Hospital1 site in 1 country36 target enrollmentMay 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prematurity
Sponsor
King Fahad Armed Forces Hospital
Enrollment
36
Locations
1
Primary Endpoint
Treatment failure
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Non-invasive respiratory support has been emerging in the management of respiratory distress syndrome (RDS) in preterm infants to minimise the risk of lung injury. Intermittent positive pressure ventilation (NIPPV) provides a method of augmenting continuous positive airway pressure (CPAP) by delivering ventilator breaths via nasal prongs.It may increase tidal volume, improve gas exchange and reduce work of breathing. However, NIPPV may associate with patient-ventilator asynchrony that can cause poor tolerance and risk of intubation. It may also in increased risk of pneumothorax and bowel perforation because of increase in intrathoracic pressure.

On the other hand, neurally adjusted ventilatory assist (NAVA) is a newer mode of ventilation, which has the potential to overcome these challenges. It uses the electrical activity of the diaphragm (EAdi) as a signal to synchronise the mechanical ventilatory breaths and deliver an inspiratory pressure based on this electrical activity. Comparing NI-NAVA and NIPPV in preterm infants, has shown that NI-NAVA improved the synchronization between patient and ventilator and decreased diaphragm work of breathing .

There is lack of data on the use of NI-NAVA in neonates post extubation in the literature. To date, no study has focused on short-term impacts. Therefore, it is important to evaluate the need of additional ventilatory support post extubation of NI-NAVA and NIPPV and also the risk of developing adverse outcomes.

Aim:

The aim is to compare NI-NAVA & NIPPV in terms of extubation failure in infants< 32 weeks gestation.

Hypothesis:

Investigators hypothesized that infants born prematurely < 32 weeks gestation who extubated to NI-NAVA have a lower risk of extubation failure and need of additional ventilatory support.

Detailed Description

Study Design: Randomised controlled trial Study Setting: single center NICU level III, KFAFH tertiary care center , Jeddah Saudi Arabia

Registry
clinicaltrials.gov
Start Date
May 1, 2017
End Date
April 30, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Raniah Aljeaid

Neonatal Fellow

King Fahad Armed Forces Hospital

Eligibility Criteria

Inclusion Criteria

  • Born less than 32 weeks gestation with respiratory distress syndrome (RDS) and requiring endotracheal tube and mechanical ventilation.
  • Less than two weeks old
  • First extubation attempt
  • CRIB score 0-5
  • Written-informed parental consent for the study

Exclusion Criteria

  • Major congenital malformations or respiratory abnormalities
  • Neuromuscular disease
  • phrenic nerve palsy
  • Intraventricular hemorrhage (IVH) grade III or IV
  • Absence of informed consent
  • Out born infants

Outcomes

Primary Outcomes

Treatment failure

Time Frame: 72 hours

1. Treatment failure during the first 72 hours post-extubation. 2. Reintubation (failure of extubation) within 72 hours' post extubation. Treatment failure is defined as: * Hypoxia (FiO 2 requirement \> 0.35) * Respiratory acidosis defined as pH \< 7.2 \& PCo2\> 60 mmHg * Major apnea requiring mask ventilation or \> 4 episodes/ hour. The protocol will discontinue according to treatment failure criteria as mentioned above. Rescue treatment with NIPPV will be allowed and will be considered as treatment failure

Secondary Outcomes

  • Intraventricular haemorrhage IVH (grades III & IV)(7 days after extubation)
  • Death prior to discharge(90 days from birth)
  • Pneumothorax(7 days after extubation)
  • Bronchopulmonary dysplasia (BPD)(36 weeks' postmenstrual age)
  • Necrotizing enterocolitis(7 days after extubation)
  • Gastrointestinal perforation(7 days after extubation)
  • Nosocomial sepsis(7 days after extubation)
  • Retinopathy of prematurity (ROP)(40 weeks corrected postnatal age)
  • Duration of hospitalisation or Length of stay (in days)(From admission to first discharge from hospital, assessed up to 6 months)

Study Sites (1)

Loading locations...

Similar Trials